The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Resistance of Candida species to fluconazole
Open accessAbstract
ASM JournalsAntimicrobial Agents and ChemotherapyVol. 39, No. 1Resistance of Candida species to fluconazole Advertisement Free access1 January 1995 Share on Resistance of Candida species to fluconazoleAuthors: J H Rex, M G Rinaldi, M A PfallerAuthors Info & AffiliationsDOI: https://doi.org/10.1128/aac.39.1.1 PDF/EPUB
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationWingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Self-citationSecular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
Azole antifungal agents: Emphasis on new triazoles
Saag, M. S., & Dismukes, W. E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.1.1 · Cited by 474
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
Antifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Self-citationWingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1847 · Cited by 340
Self-citationSangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Self-citation
Cited by
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
van Burik, J.-A. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J. W., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 744
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations
Sobel, J. D., Faro, S., Force, R. W., Foxman, B., Ledger, W. J., Nyirjesy, P. R., Reed, B. D., & Summers, P. R. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80001-x · Cited by 694
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601
“glabrata) in patients receiving fluconazole [23-25].”
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Akpan, A., & Morgan, R. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.922.455 · Cited by 578
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523
Antifungal agents: chemotherapeutic targets and immunologic strategies
Georgopapadakou, N. H., & Walsh, T. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.279 · Cited by 498
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Molecular basis of resistance to azole antifungals.
Lupetti, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02280-3 · Cited by 449
Turenne, C. Y., Sanche, S. E., Hoban, D. J., Karlowsky, J. A., & Kabani, A. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1846-1851.1999 · Cited by 435
Ahmad, A., Khan, A., Akhtar, F., Yousuf, S., Xess, I., Khan, L. A., & Manzoor, N. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1050-8 · Cited by 431
Pfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423
Self-citationFluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Natural products – antifungal agents derived from plants
Arif, T., Bhosale, J. D., Kumar, N., Mandal, T. K., Bendre, R. S., Lavekar, G. S., & Dabur, R. (2009) · Journal of Asian Natural Products Research · doi:10.1080/10286020902942350 · Cited by 406
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2300 · Cited by 402
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
“These studies resulted in a series of reviews dedicated to this subject (Bodey, 1997; De Muri & Hostetter, 1995; Denning et al., 1997; Dupont, 1995; Frosco & Barrett, 1998; Hartman & Sanglard, 1997; Johnson & Warnock, 1995; Joseph-Horn & Hollomon, 1997; Marichal & Vanden Bossche, 1995; Odds, 1998; Rex et al., 1995; Sa…”
BackgroundGroll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
The Ins and Outs of DNA Fingerprinting the Infectious Fungi
Soll, D. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.332 · Cited by 346
Candiduria: A Randomized, Double-Blind Study of Treatment with Fluconazole and Placebo
Sobel, J. D., Kauffman, C. A., McKinsey, D., Zervos, M., Vazquez, J. A., Karchmer, A. W., Lee, J., Thomas, C., Panzer, H., Dismukes, W. E., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313580 · Cited by 343
“glabrata is frequently reported to demonstrate intrinsic resis ance to fluconazole; hence, our findings were not anticipated, especially given the high frequency with which his species was found (20%) in candiduric patients [25].”
ResultFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
“While C. albicans remains the principal agent of OPC, C. glabrata is often recovered from clinical samples in addition to C. albicans.”
BackgroundInfluentialThe Biological Activity of Natural Alkaloids against Herbivores, Cancerous Cells and Pathogens
Thawabteh, A., Juma, S., Bader, M., Karaman, D., Scrano, L., Bufo, S., & Karaman, R. (2019) · Toxins · doi:10.3390/toxins11110656 · Cited by 334
Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331
“Recently, however, fluconazole-refractory oral candidiasis has emerged as an increasing problem [10, 15], and therapeutic failures have been reported in ∼ 5% of cases of oropharyngeal or esophageal candidiasis in patients with advanced AIDS [16].”
BackgroundInfluentialPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331
Self-citationSynthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues
Aher, N. G., Pore, V. S., Mishra, N. N., Kumar, A., Shukla, P. K., Sharma, A., & Bhat, M. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.026 · Cited by 328
Discovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J., Meinz, M., Thompson, J., Curotto, J., Dreikorn, S., Rosenbach, M., Douglas, C., Abruzzo, G., Flattery, A., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 326
Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle
Zore, G. B., Thakre, A. D., Jadhav, S., & Karuppayil, S. M. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.03.008 · Cited by 319
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292
Onyewu, C., Blankenship, J. R., Del Poeta, M., & Heitman, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.956-964.2003 · Cited by 282
Principles of Judicious Use of Antimicrobial Agents for Pediatric Upper Respiratory Tract Infections
Dowell, S. F., Marcy, S. M., Phillips, W. R., Gerber, M. A., & Schwartz, B. (1998) · Pediatrics · doi:10.1542/peds.101.s1.163 · Cited by 275
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
Albertson, G. D., Niimi, M., Cannon, R. D., & Jenkinson, H. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2835 · Cited by 260
Al-Tel, T. H., Al-Qawasmeh, R. A., & Zaarour, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.051 · Cited by 252
Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609370104 · Cited by 248
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239
CRZ1 , a target of the calcineurin pathway in Candida albicans
Karababa, M., Valentino, E., Pardini, G., Coste, A. T., Bille, J., & Sanglard, D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.05037.x · Cited by 231
Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
Self-citationRole of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism
Silver, P. M., Oliver, B. G., & White, T. C. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1391-1397.2004 · Cited by 216
“Resistance to the azole and polyene class drugs has been documented clinically (18).”
BackgroundEmpirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
“3 ULN) 129 39 (30) 134 25 (19) Elevated platelet count ( 700 10(9) cells/L) 127 15 (12) 131 24 (18) Elevated alanine aminotransferase level ( 3.”
InfluentialSelf-citationMolecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210
Moran, G. P., Sanglard, D., Donnelly, S. M., Shanley, D. B., Sullivan, D. J., & Coleman, D. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1819 · Cited by 197
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195
“Previous determination of Candida species breakpoints was based on studies conducted on blood and oropharyngeal isolates, ignoring specific pharmacokinetic considerations applicable to the vagina.(12,13) The breakpoint or measurement of in vitro fluconazole resistance in C albicans had recently been reduced by the Cli…”
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
“albicans is a phenomenon that has not been reported to occur in patients with HIV infection (21).”
BackgroundHernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
“glabrata for which the fluconazole MICs are 64 g/ml have been associated with clinical failure of fluconazole therapy (14, 15).”
BackgroundProphylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
“Most studies have focused on the use of azoles—most notably, fluconazole—so it is not surprising that the majority of the reports on this topic have focused on azole resistance [19].”
BackgroundSelf-citationAntifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Evolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151
The Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent
Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1383 · Cited by 145
Self-citationExperimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145
Haemin uptake and use as an iron source by Candida albicans: role of CaHMX1-encoded haem oxygenase
Santos, R., Buisson, N., Knight, S., Dancis, A., Camadro, J.-M., & Lesuisse, E. (2003) · Microbiology · doi:10.1099/mic.0.26108-0 · Cited by 139
“Prolonged neutropenia, following cancer chemotherapy or bone marrow transplantation, is a major risk factor for invasive fungal infections, and Candida species are the most frequently implicated organisms (Rex et al., 1995).”
BackgroundInfluentialTrends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital
Berrouane, Y. F., Herwaldt, L. A., & Pfaller, M. A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.531-537.1999 · Cited by 136
Self-citationSt-Germain, G., Laverdière, M., Pelletier, R., Bourgault, A.-M., Libman, M., Lemieux, C., & Noël, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.949-953.2001 · Cited by 134
“Resistance was first reported in AIDS patients with recurrent oropharyngeal candidiasis and is still seldom seen outside this patient group (22).”
BackgroundMolecular aspects of fluconazole resistance development in Candida albicans
Franz, R., Ruhnke, M., & Morschhäuser, J. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00498.x · Cited by 129
Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis
Yera, H., Sendid, B., Francois, N., Camus, D., & Poulain, D. (2001) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s100960100629 · Cited by 119
Macphail, G. L. P., Taylor, G. D., Buchanan‐Chell, M., Ross, C., Wilson, S., & Kureishi, A. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00741.x · Cited by 119
White, T., Pfaller, M., Rinaldi, M., Smith, J., & Redding, S. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00336.x · Cited by 107
Self-citationMalik, I. A., Moid, I., Aziz, Z., Khan, S., & Suleman, M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00326-x · Cited by 106
Identification and expression of multidrug resistancerelated ABC transporter genes in Candida krusei
Katiyar, S. K., & Edlind, T. D. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.109.116 · Cited by 104
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases · doi:10.1086/515006 · Cited by 103
Formation of Azole-Resistant Candida albicans by Mutation of Sterol 14-Demethylase P450
Asai, K., Tsuchimori, N., Okonogi, K., Perfect, J. R., Gotoh, O., & Yoshida, Y. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1163 · Cited by 102
Chin, N. X., Weitzman, I., & Della-Latta, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.850 · Cited by 101
Talibi, D., & Raymond, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.1.231-240.1999 · Cited by 101
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100
Pfaller, M. A., Lockhart, S. R., Pujol, C., Swails-Wenger, J. A., Messer, S. A., Edmond, M. B., Jones, R. N., Wenzel, R. P., & Soll, D. R. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.6.1518-1529.1998 · Cited by 91
“(14, 18, 19, 21), it is now crucial that the origins and possible specialization of nosocomial strains of Candida be investigated.”
BackgroundSelf-citationRamani, R., & Chaturvedi, V. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2752-2758.2000 · Cited by 90
Wirsching, S., Michel, S., Köhler, G., & Morschhäuser, J. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.2.400-404.2000 · Cited by 88
“Especially in patients with AIDS who have recurrent OPC and who are receiving prolonged fluconazole therapy, treatment failures are due to the emergence of fluconazole-resistant strains (10, 22).”
BackgroundRognon, B., Kozovska, Z., Coste, A. T., Pardini, G., & Sanglard, D. (2006) · Microbiology · doi:10.1099/mic.0.29277-0 · Cited by 71
Kontoyiannis, D. P. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.191 · Cited by 70
Mathema, B., Cross, E., Dun, E., Park, S., Bedell, J., Slade, B., Williams, M., Riley, L., Chaturvedi, V., & Perlin, D. S. (2001) · Clinical Infectious Diseases · doi:10.1086/322600 · Cited by 65
Wang, H., Kong, F., Sorrell, T. C., Wang, B., McNicholas, P., Pantarat, N., Ellis, D., Xiao, M., Widmer, F., & Chen, S. C. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-167 · Cited by 58
Key issues concerning fungistatic versus fungicidal drugs
Graybill, J. R., Burgess, D. S., & Hardin, T. C. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01575120 · Cited by 59
“Are these data inconsistent with reports of clinical failure for fluconazole-resistant Candida krusei ( 13 )? We do not think so, for such failures occurred in severely immunodeficient patients, in which the outcome relied more heavily on an effective antifungal drug and less on a boost from host immune defenses.”
BackgroundReversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs
Eldesouky, H. E., Mayhoub, A., Hazbun, T. R., & Seleem, M. N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-17 · Cited by 55
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1997) · Clinical Infectious Diseases · doi:10.1086/515554 · Cited by 54
“albicans to fluconazole has become an increasingly recognized problem for the HIV-infected population, and this topic has been recently reviewed [16].”
BackgroundSelf-citationT., B., W., F., H., B., N., B., K.-H., D., M., H., D., H., U., J., G., J.-N., M., K., et al. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0730-4 · Cited by 53
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Chang, H. C., Chang, J. J., Chan, S. H., Huang, A. H., Wu, T. L., Lin, M. C., & Chang, T. C. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1328-1333.2001 · Cited by 48
“There are two reasons for this: (i) amphotericin B resistance and therapeutic failure have been reported for several Candida species (12, 16, 27), and (ii) an expanding list of fluconazole-resistant fungi has also been reported (3, 21, 28, 29, 31).”
BackgroundAzole Antifungal Resistance Today: Focus on Aspergillus
Bowyer, P., Moore, C. B., Rautemaa, R., Denning, D. W., & Richardson, M. D. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0218-4 · Cited by 44
Respiration, oxidative phosphorylation, and uncoupling protein in Candida albicans
Cavalheiro, R. A., Fortes, F., Borecký, J., Faustinoni, V. C., & Schreiber, A. Z. (2004) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2004001000003 · Cited by 44
Arana, D. M., Nombela, C., & Pla, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp407 · Cited by 35
Metadata
- Authors
- Rex, J. H., Rinaldi, M. G., & Pfaller, M. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1995-01
- Volume
- 39
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1973697574
- Cited by
- 877
- References
- 70
- FWCI
- 61.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.